Ignite Creation Date:
2024-05-06 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 2:14 PM
Study NCT ID:
NCT05067166
Status:
AVAILABLE
Last Update Posted:
2024-05-03
First Post:
2021-09-23
Brief Title:
Open-Label Expanded Access for Ebola-Infected Patients to Receive Human mAb Ansuvimab as Therapeutic or for HR PEP
Sponsor:
Ridgeback Biotherapeutics LP
Organization:
Ridgeback Biotherapeutics LP
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Hemorrhagic Fever Ebola |
Keywords:
| Name | View |
|---|---|
| Zaire ebolavirus EVD EBANGA compassionate use | View |